Skip to main
GMAB
GMAB logo

GMAB Stock Forecast & Price Target

GMAB Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Genmab reported operating income that exceeded expectations by 20%, highlighting the company's efficient management and robust financial performance amidst a challenging biotech sector. The ongoing success of Darzalex, along with its promising pipeline of candidates set to yield pivotal read-outs by 2026, positions Genmab well for future revenue growth and diversification. With approximately $3.4 billion in cash and marketable securities, Genmab's strong balance sheet supports its capability to navigate potential market fluctuations while capitalizing on significant future opportunities.

Bears say

The analysis of Genmab's financial outlook reveals a series of substantial risks contributing to a negative sentiment regarding the stock's future performance. Key concerns include slowing sales of Genmab's flagship product, Darzalex, potential failures in obtaining label extensions, unanticipated negative readouts from ongoing trials, and a lack of market penetration for emerging products like Epcoritamab. Additionally, the decision to discontinue development of the program GEN1042 and uncertainties surrounding clinical or regulatory outcomes for critical pipeline products intensify the outlook, raising questions about the company's long-term growth prospects and market competitiveness.

GMAB has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Genmab - ADR (GMAB) Forecast

Analysts have given GMAB a Strong Buy based on their latest research and market trends.

According to 4 analysts, GMAB has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Genmab - ADR (GMAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.